Preparing For Off-Label Drug Use In The Real World (Part 1 Of 2)

06 Jan 2012

• By Michael Goodman

Plans are acquiring the tools to monitor and assess the risk/benefit of drug use outside of the approved indication. Smart companies are working with payers to understand their concerns around off-label use and the data requirements in support of it.

Industry’s current fixation on “real world data” has a consequence: It may shed more light on off-label drug use.

As large health care delivery systems introduce treatment pathways and guidelines, the use of e-health cards becomes routine, and health...